news

What this article doesn't mention is that some patients will be better able to tolerate the "copycat" version of the first drug to market. It is often true that when a company introduces slightly "tweaked" drug very similar to one it already has on the market that this is just a patent extension strategy.

Ultimately though, it is to the patient's benefit to have some choices in drug classes. This gives them a better chance to find a drug that they can tolerate and still be effective.